From early detection and hereditary risk to advanced therapy selection and recurrence monitoring โ our portfolio covers the full continuum of precision oncology.
A simple blood draw. Comprehensive molecular insight.
A non-invasive blood test that detects circulating tumor DNA (ctDNA) and analyzes thousands of genomic alterations to guide treatment decisions and monitor disease progression.
The most extensive molecular profile available.
Whole exome and whole transcriptome sequencing of solid tumors โ uncovering actionable biomarkers, fusions, and signatures to match patients with the most effective targeted therapies and clinical trials.
Predict late recurrence. Personalize endocrine therapy.
A genomic test that predicts the risk of late distant recurrence (years 5โ10) in HR+ breast cancer and identifies which patients benefit from extended endocrine therapy.
A smarter blood test before prostate biopsy.
A blood test that measures four prostate-specific kallikrein proteins and combines them with clinical information to estimate the risk of aggressive (Gleason โฅ7) prostate cancer โ helping men and their physicians decide whether a biopsy is truly needed.
Know your inherited risk.
Multi-gene germline panel including BRCA1/2, Lynch syndrome, and other high-penetrance genes โ for patients and families with a history of cancer.
Detect cancer before it returns.
Ultra-sensitive ctDNA monitoring designed to detect molecular residual disease after treatment, often months before clinical or radiographic recurrence.